CION Ameerpet
If someone you love has just been diagnosed with glioblastoma, you are likely searching for one number. The honest answer is a range, not a single figure — and we will help you understand what it really means for your family.
When a family receives a glioblastoma (GBM) diagnosis, the first question is almost always the hardest: how long? You deserve an honest answer, and the honest answer is that there is no single survival figure — outcomes vary widely from person to person. What the published evidence gives us is a range and a set of averages, not a prediction for any one individual.
With the standard treatment sequence — maximal safe surgery, then radiation given together with alkylating chemotherapy, followed by further chemotherapy — large studies report a median overall survival of about 15 to 18 months, and roughly 5% to 10% of patients are alive at 5 years. "Median" simply means the midpoint: half of patients live longer than this, half shorter. It is a statistic about thousands of people, not a countdown clock for your loved one.
Glioblastoma is the WHO Grade 4 form of glioma (GBM) — the most aggressive primary brain tumour in adults. Understanding what drives the numbers up or down is the first step to making clear, calm decisions. Learn more about brain tumours and brain cancer on our hub.
The landmark trial that set the modern standard of care for glioblastoma (the EORTC-NCIC / "Stupp" trial, published in the New England Journal of Medicine, 2005) reported a median overall survival of 14.6 months when radiation was combined with alkylating chemotherapy, versus 12.1 months with radiation alone — and a 2-year survival of 27% versus 10%. Both NCCN and EANO guidelines stress that these figures are group averages: an individual's outlook depends heavily on age, how much tumour was safely removed, and molecular markers such as MGMT methylation.
Numbers help you understand the landscape and ask better questions. They were never designed to predict one person's journey. Holding both truths at once makes the decisions ahead a little clearer.
Survival ranges describe how groups of patients with GBM have done in the past. They help your team plan treatment intensity, set realistic expectations, and decide when a clinical trial or a second opinion might add value. They are a starting point for honest conversation, not the final word.
A median or a 5-year percentage cannot tell you what will happen to your family member. Older data does not capture newer treatment combinations, individual molecular markers like IDH and MGMT, or how well a particular person responds. Two people of the same age can have very different outcomes — so please do not read a statistic as a deadline.
The most reliable outlook comes from your own neuro-oncologist, after reviewing the MRI, the surgical pathology, and the molecular results together. CION provides a 45-minute consultation to explain all of this in plain language, plus a free written second opinion. Book a conversation with our team.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
Whether you need the prognosis explained gently, a treatment plan reviewed, or a free second opinion — CION's neuro-oncology team is here. We make decisions for healing, not billing.
Survival varies so much because GBM is not one disease — it is many subtypes with different biology. Below are the factors that, in published data and in guidelines from NCCN and EANO, most strongly influence GBM prognosis. Your neuro-oncologist weighs all of them together; no single factor decides the outcome on its own.
MGMT is a DNA-repair gene. When its promoter is "methylated" (effectively switched off), the tumour struggles to repair the damage caused by alkylating chemotherapy — so the chemotherapy works better. In published studies, patients with a methylated MGMT tumour had a median survival of roughly 23 months, compared with about 12 to 15 months for unmethylated tumours on the same protocol. This single test result can meaningfully change both the treatment plan and what to expect, which is why CION arranges it on every malignant glioma sample. Read more about glioblastoma (GBM).
IDH (isocitrate dehydrogenase) status is a key molecular marker. Under the 2021 WHO classification, the term "glioblastoma" is now reserved for IDH-wild-type tumours, which tend to be more aggressive. Tumours that were previously called IDH-mutant glioblastoma are now classified and treated as a distinct, generally slower-growing and more favourable astrocytoma. Knowing IDH status is essential for an accurate diagnosis, an accurate prognosis, and the right treatment plan — so it should always be tested on a malignant glioma biopsy.
Age is one of the strongest prognostic factors. Younger adults — broadly under 50 — live significantly longer on average than patients over 65. This is partly tumour biology and partly because younger, fitter patients tolerate full-intensity treatment more easily. It is an average, not a rule: older patients with good fitness and a methylated MGMT tumour can also do well, and treatment can be carefully tailored to be effective yet tolerable for older adults.
Performance status describes how well someone can carry out everyday activities. Patients who are up, about, and largely independent at diagnosis generally tolerate treatment better and live longer on average than those who are already very unwell. This is why your team assesses overall fitness — not just the scan — before recommending a plan. Supportive care, steroids, seizure management, and rehabilitation can all help preserve performance status during treatment.
The more tumour that can be safely removed, the better the average outcome — gross total resection is associated with longer survival than partial removal or biopsy alone. The word "safely" matters: surgeons remove as much as possible without harming the brain areas that control speech and movement. At CION, all neurosurgery — including maximal safe resection and stereotactic biopsy — is coordinated with accredited neurosurgical partners, while CION directly delivers radiation, systemic therapy, imaging, molecular testing, and supportive care.
How the tumour responds to the first phase of treatment shapes the outlook, but early scans can be deceptive. A phenomenon called pseudoprogression can make the first MRI after chemoradiation look worse than the tumour actually is, because of post-treatment inflammation rather than true growth. Experienced neuro-oncologists recognise this and avoid changing the plan prematurely. This is one reason a second opinion can be so valuable. Understand prognosis for advanced or aggressive brain tumours.
All figures above are published ranges and group averages drawn from NCCN and EANO guidance and clinical-trial data. They describe populations, not individuals, and should never be read as guarantees.
A glioblastoma diagnosis affects the whole family — not just the patient. CION's role is to give you clarity, the best possible treatment, and steady support throughout. Here is what our team delivers directly:
A gentle note on the goal: for most patients, glioblastoma is treated as a long-term condition to be controlled rather than cured — and we will never promise a cure. What good care can do is extend meaningful time, control symptoms, and protect quality of life. Some patients live well beyond the median for several years. Talk to a CION specialist about a realistic, personalised plan, or explore brain tumour treatment in Hyderabad.
For glioblastoma, a second opinion is not about doubting your doctors — it is about making sure nothing that could change the outlook has been missed. Consider one in these situations:
CION offers a dedicated, free written second opinion reviewed by our neuro-oncology tumour board. Start with the brain cancer & tumour hub, or call us on 18002028726 to speak to a specialist today.
Survival statistics are built from data collected in the past — they cannot account for newer treatment combinations or for how a particular person responds. According to EANO and NCCN guidance, an individual's prognosis should be discussed using their own age, fitness, extent of resection, and molecular markers — not a single headline figure. That is why CION pairs honest information with a personalised plan: clarity and compassion belong together.
A free written second opinion from CION's neuro-oncology tumour board — so you understand the prognosis clearly and know every option available to your family.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.With the standard treatment sequence — surgery, then radiation given together with chemotherapy, then more chemotherapy — published studies report a median overall survival of about 15 to 18 months for glioblastoma (GBM). The original trial that set this standard reported a median of around 14.6 months. "Median" means half of patients live longer than this figure and half shorter — it is a midpoint, not a deadline. NCCN and EANO guidelines both describe outcomes as a wide range, not a single number, because age, the amount of tumour safely removed, and tumour biology vary a lot between people.
Across large registry data, roughly 5% to 10% of glioblastoma patients are alive at 5 years. Younger patients, those whose tumour was almost completely removed, and those whose tumour carries a methylated MGMT gene make up most long-term survivors. These figures come from historical data and group averages — they cannot predict any one person's outcome. New treatment combinations are studied in clinical trials, and a CION neuro-oncologist can explain what the most current evidence means for your specific situation.
MGMT is a DNA-repair gene. When its promoter is "methylated" (switched off), the tumour cannot repair damage from alkylating chemotherapy as easily, so the chemotherapy works better. In published studies, patients with a methylated MGMT tumour had a median survival of roughly 23 months versus about 12 to 15 months for unmethylated tumours on the same protocol. This is why CION arranges MGMT and IDH molecular testing on the biopsy of every malignant glioma — the result genuinely changes both the plan and what to expect.
Yes. Age is one of the strongest prognostic factors. Younger adults — broadly under 50 — tend to live significantly longer on average than patients over 65, partly because they tolerate full-intensity treatment better and partly due to tumour biology. A person's performance status (how active and independent they are at diagnosis) matters just as much. Two people of the same age can have very different outlooks. These are averages across thousands of patients, not a prediction for any individual.
For most patients, glioblastoma is not currently curable — it is treated as a long-term condition to be controlled. We will never promise a cure. What modern treatment can do is meaningfully extend survival, control symptoms, and protect quality of life. Some patients live well beyond the median for several years. The honest goal of the CION tumour board is the best possible time, with the best possible quality of life — and full clarity at every step. Speak to our team about a realistic, personalised plan.
Survival statistics describe large groups of people studied in the past — they cannot tell you what will happen to one person. They do not account for newer treatments, individual molecular markers like IDH and MGMT, or how well someone responds. Use them to understand the general landscape and to ask better questions, not as a countdown. The most reliable picture comes from your own neuro-oncologist after reviewing the MRI, the surgical pathology, and the molecular results together.
A glioblastoma diagnosis affects the whole family. CION delivers more than treatment: a 45-minute consultation to explain the diagnosis in plain language, a multidisciplinary tumour board for every patient, steroid and seizure management, supportive and rehabilitation care, and a free written second opinion. We make decisions for healing, not billing, and we walk this journey with you — across 35+ centres with transparent costs. Request a callback to talk to a specialist today.
Disclaimer: This content is intended for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Survival figures are published ranges and group averages — they describe populations, not individuals, and are not predictions or guarantees for any one patient. Always consult a qualified oncologist for guidance specific to your medical condition. This page is periodically reviewed and updated by CION's medical team in accordance with current clinical guidelines, including NCCN and EANO.
Browse our complete guide to brain tumours and brain cancer — symptoms, scans, tumour types, treatment, prognosis and life after treatment. Tap any topic to read more.